Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71432 | 0.89 | AKR1C3 (0.61) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| Water SCHEMBL27971095 | 0.87 | AKR1C3 (0.59) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| SCHEMBL29118338 | 0.81 | AKR1C3 (0.71) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| SCHEMBL30517803 | 0.81 | AKR1C3 (0.66) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| SCHEMBL5235780 | 0.81 | AKR1C3 (0.66) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| Toluene SCHEMBL28189299 | 0.80 | AKR1C3 (0.56) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| SCHEMBL16792377 | 0.80 | AKR1C3 (0.51) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| SCHEMBL11000519 | 0.79 | AKR1C3 (0.54) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| SCHEMBL13369193 | 0.78 | AKR1C3 (0.61) | AKR1C3KMONR4A2KMT2AMRGPRX4 | |
| SCHEMBL68858 | 0.77 | AKR1C3 (0.92) | AKR1C3KMONR4A2KMT2AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113651758-B | Synthetic method of benzo-hydrogenated imidazolone framework | 南通大学 | 2023-03-14 | — | — | CN | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3601282-A1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-20180327425-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2018178041-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-04 | — | — | WO | disclosed |
| EP-2330909-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8383635-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2330909-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2010019637-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327425-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | AKR1C3 262/4885KMO 7/4885NR4A2 2627/4885 |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | AKR1C3 262/4885KMO 7/4885NR4A2 2627/4885 |
| US-20110136838-A1 | CHEMICAL COMPOUNDS | PDK1, PDK4, PDK3 | AKR1C3 181/4885KMO 844/4885NR4A2 2996/4885 |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, KYNU | AKR1C3 195/4885KMO 7/4885NR4A2 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.